NEW YORK (TheStreet
) -- CHANGE IN RATINGS
Dr. Pepper Snapple
DPS was upgraded at Morgan Stanley from Underweight to Equal-Weight. U.S. business environment is improving, Morgan Stanley said.
FB was initiated with a Buy rating at Sterne Agee. $46 price target. Company can continue to grow through China and mobile advertising, Sterne Agee said.
Genesee & Wyoming
GWR was upgraded at Dahlman Rose from Hold to Buy. $67 price target. A lot of growth headwinds are now behind the company, Dahlman Rose.
ILMN was upgraded at Credit Suisse from Neutral to Outperform. $55 price target. Company has returned to sequential growth, and the company can continue to penetrate the clinical market, Credit Suisse said.
LEA was upgraded at Morgan Stanley from Underweight to Overweight. Consensus expectations have fallen to a reasonable level, Morgan Stanley said. $55 price target.
LM was upgraded at Sterne Agee to Neutral. Valuation call, based on a $28 price target, Sterne Agee said.
LNT was downgraded at Wunderlich from Buy to Hold. $45 price target. Company likely to see lower regulated earnings in Wisconsin, Wunderlich said.
LOW was upgraded at Morgan Stanley from Equal-Weight to Overweight. Industry can sustain moderate growth over the next several years, Morgan Stanley said. $38 price target.
Leucadia National Corp.
LUK was upgraded to Buy at TheStreet Ratings.
MUR was downgraded at Brean Murray to Hold. Malaysia continues to weigh on overall growth, Brean Murray said.
NWL was upgraded at Oppenheimer to Outperform from Perform. $23 price target. Pieces to growth story now in place, Oppenheimer said.
PCLN was upgraded at Nomura from Reduce to Neutral. $725 price target. U.S. business can continue to drive growth, Nomura said.
PEP was upgraded at Morgan Stanley from Equal-Weight to Overweight. $77 price target. Higher marketing spending should pay off, or management can take more drastic measures, Morgan Stanley said.
Procter & Gamble
PG was downgraded at Wells Fargo from Outperform to Market Perform. Company lacks near-term catalysts, Wells Fargo said.
RP was downgraded to Sell at TheStreet Ratings.
STOCK COMMENTS / EPS CHANGES
ALL estimates, price target were increased at Credit Suisse. Estimates were raised through 2013. Company is seeing better growth across the board, Credit Suisse said. Outperform rating and new $35 price target.
CBT numbers were raised at Jefferies. Shares are now seen reaching $53. Estimates were also raised on first-quarter earnings results, Jefferies said.
Clear Channel Outdoor
CCO numbers were cut at UBS. Shares are now seen reaching $7. Estimates were also reduced, as the company is seeing lower sales and higher costs, UBS said. Neutral rating.
Church & Dwight
CHD target was raised at Oppenheimer. Shares are now seen reaching $58, Oppenheimer said. Healthy organic sales growth, Oppenheimer said. Outperform rating.
DVN numbers were reduced at Guggenheim. Estimates were cut through 2013. Company is leveraged to lower energy prices, Guggenheim said. Buy rating and new $90 price target.
DVN numbers were lowered at Jefferies. Shares are now seen reaching $93. Estimates were also lowered on first-quarter earnings performance. Buy rating.
LLY numbers were raised at Bank of America/Merrill Lynch. Estimates were raised through 2014. Company has solid late-stage clinical assets, BofA/Merrill Lynch said. Buy rating and new $46 price target.
VRX estimates, price target were raised at Morgan Stanley. Shares are now seen reaching $61. Estimates also increased, given recent strategic deals, Morgan Stanley said. Overweight rating.
WLL numbers were boosted at Credit Suisse. Shares are now seen reaching $83. Estimates were also upped, given the company's new guidance, Credit Suisse said. Outperform rating.
>To submit a news tip, email: firstname.lastname@example.org
READERS ALSO LIKE:
and become a fan on Facebook.